The Bombay High Court directs the Maharashtra FDA to withdraw its order cancelling Cipla’s Pune licence, after the court criticises the regulator for acting “overboard.” Following the court’s remarks, the FDA withdraws the cancellation order.
The outlets report that the court finds the action violates principles of natural justice, prompting a change in process. NDTV and Business Line say the FDA will issue a fresh show-cause notice to Cipla, after which it will pass a reasoned decision based on the company’s response. India Today similarly notes that the court’s order leads to the withdrawal of the cancellation order.
While the core facts are consistent across sources—court criticism, withdrawal of the cancellation, and a renewed notice—outlets differ slightly in emphasis. NDTV focuses on the FDA’s commitment to withdraw “forthwith” and issue a new notice for a reasoned order. Business Line highlights the natural-justice grounds for the court’s intervention. India Today frames the issue around the court’s assessment that the FDA went beyond acceptable bounds.
